NCT03763318 - A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

November 21, 2022

Study Completion Date

November 21, 2022

Conditions

Acute-graft-versus-host DiseaseaGVHDGVHDGVHD, Acute

Interventions

BIOLOGICAL

EQ001

Itolizumab \[Bmab 600\])

BIOLOGICAL

EQ001 Placebo

Trial Locations (16)

14263

Roswell Park Cancer Institute, Buffalo

15232

University of Pittsburgh Cancer Institute, Pittsburgh

19104

University of Pennsylvania, Abramson Cancer Center, Philadelphia

27599

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill

30322

Emory University Hospital, Atlanta

32610

University of Florida Health Shands Hospital, Gainesville

33136

University of Miami - Miller School of Medicine, Miami

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

48109

University of Michigan - C.S. Mott Children's Hospital, Ann Arbor

53719

TriStar Centennial Medical Center (SCRI), Nashville

63110

Washington University and Barnes Jewish Heart & Vascular Center, St Louis

84103

Intermountain Healthcare, Salt Lake City

91010

City of Hope Comprehensive Cancer Center, Duarte

97239

Oregon Health & Science University, Portland

02215

Dana-Farber Cancer Institute, Boston

98109-4433

Fred Hutchinson Cancer Research Center, Seattle